. . . . "investigational"@en . . . . . . . "152044-54-7"@en . . . . "Humans and other mammals"@en . "Richard Taylor, \"Derivatives of epothilone B and D and synthesis thereof.\" U.S. Patent US20030176473, issued September 18, 2003."@en . . . . . "Epothilone B is a 16-membered macrolide that mimics the biological effects of taxol."@en . . . . . . "EPO906"@en . "Epothilone B"@en . "EPO 906"@en . . . . . "experimental"@en . "The principal mechanism of the epothilone class is inhibition of microtubule function. Microtubules are essential to cell division, and epothilones therefore stop cells from properly dividing. Epothilone B possess the same biological effects as taxol both in vitro and in cultured cells. This is because they share the same binding site, as well as binding affinity to the microtubule. Like taxol, epothilone B binds to the \u03B1\u03B2-tubulin heterodimer subunit. Once bound, the rate of \u03B1\u03B2-tubulin dissociation decreases, thus stabilizing the microtubules. Furthermore, epothilone B has also been shown to induce tubulin polymerization into microtubules without the presence of GTP. This is caused by formation of microtubule bundles throughout the cytoplasm. Finally, epothilone B also causes cell cycle arrest at the G2-M transition phase, thus leading to cytotoxicity and eventually cell apoptosis."@en . "patupilone"@en . . . . . "Investigated for use/treatment in ovarian cancer, lung cancer, brain cancer, breast cancer, and gastric cancer."@en . . . " "@en . . .